Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Safety, efficacy, and compliance of moderate-to-high dose eptinezumab and erenumab in chronic migraine patients with medication-overuse headache: an updated systematic review and meta-analysis

Fig. 3

Safety and Efficacy Outcomes of Anti-CGRP Therapy (Eptinezumab 100 mg and Erenumab 70 mg, standard dose therapy). A: At least a 50% reduction in MMDs from baseline with at least 12 weeks of treatment. B: Remission of MOH with at 6 months of treatment. C: Risk of TESAEs. All analyses used a p value < 0.05, with 95% confidence intervals exclude null value of 1 as statistical significant results

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us